Home » Newsletters » BioWorld Science

BioWorld Science

July 6, 2006

View Archived Issues

Preclinical update on the vascular benefits of NCX-6550

Potential of EGFR-related protein in colorectal cancer treatment examined in vivo

Ezetimibe/simvastatin superior to rosuvastatin in primary hypercholesterolemia

Recent results with bevacizumab in gastrointestinal cancers

ACZ-885 induces remission in Muckle Wells syndrome

TRU-015 pharmacodynamics assess in rheumatoid arthritis patients

Preclinical analysis of the antidepressive effects of galanin-3 receptor antagonism

Avastin studied in Australian trial for age-related macular degeneration

Innovate Oncology changes name to Avantogen Oncology

EQiTX restructures synthetic vaccine project

Norwood completes pilot BMT study in Australia

ABIO 08-01 begins Austrian phase II study in generalized anxiety disorder

OctoPlus acquires full rights to OP-145

FDA clears protocol amendment for phase I/II trials of HMPL-002

Sanofi-aventis licenses oral anticancer agent S-1 from Taiho

Biofusion invests in Adjuvantix

MK-677 slows sarcopenia in healthy elderly subjects

EP-01572 pharmacokinetics, pharmacodynamics evaluated in healthy men

Nicosan approved in Nigeria

A prodrug of 3-n-butylphtalide (NBP) may be useful for the treatment of cerebral ischemia

DiaPep277 mechanism of action involves TLR2-dependent modulation of regulatory T cell function

New lembehyne analogue shows antitumor activity in human neuroblastoma cell line

Recent patents disclose novel agents for gastrointestinal disorders

Dual NOS/COX-2 inhibitors claimed in Asineks patent

Recent patents describe novel treatment options for diabetes and associated disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...